French microbiome company Enterome is teaming up with Swiss nutritionals giant Nestlé Health Science to form a joint venture focused on developing microbiome-based diagnostics. Nestlé will invest €20m ($23m) in return for a 50% stake in Microbiome Diagnostics Partners (MDP). In addition, it will make further payments to MDP if it achieves certain clinical and commercial milestones. Enterome will contribute to the JV its current microbiome diagnostic programs and intellectual property derived from its microbiome-based platforms.
The main focus of the joint venture will be to accelerate commercialization of Enterome's diagnostic platforms which include IBD110, a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?